30 June 2014

"The JSE's Issuer Regulation division is investigating the circumstances of last Friday's Aspen Pharmacare investor conference call in order to determine if there was any contravention of JSE Listings Requirements.  The exchange's Market Regulation division is reviewing trading ahead of the conference call and the subsequent decline in Aspen's share price on Friday.  If there is any trading that it believes warrants further investigation, this will be referred to the Directorate of Market Abuse at the Financial Services Board as is standard practice."​